Biotechnology · NASDAQ
当前价格
$52.56
内在价值
使用下方计算器估算
对 Moderna, Inc. 运行完整的 DCF 分析，自动填充基本面数据，可调节假设参数，含敏感性热力图。
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
ROIC (TTM)
-29.7%
ROE (TTM)
-30.1%
FCF Yield
-9.89%
基于过去 12 个月的数据，MRNA 每股自由现金流为 N/A，投入资本回报率（ROIC）为 -29.7%，这些是使用 DCF 方法进行股票估值的关键输入。P/FCF 比率为 N/A，FCF 收益率为 -9.89%，是评估 MRNA 相对估值的重要参考指标。
MRNA 的内在价值取决于对未来增长率、折现率（WACC）和终值的假设。使用 MiniValuator 免费 DCF 计算器，输入你自己的假设进行估算，并查看敏感性分析热力图。
MRNA 是否被低估取决于你的 DCF 假设。如果计算出的内在价值显著高于当前市价，则可能被低估。安全边际指示低估程度。在 MiniValuator 上运行完整估值来了解。
你可以使用 MiniValuator 的 DCF 计算器对 MRNA 估值：输入代码，查看自动填充的基本面数据，调整增长率和折现率假设，即可获得含敏感性热力图的即时内在价值。
DCF（折现现金流）估值通过将公司未来预期自由现金流折现回现值来估算内在价值。对于 MRNA，你输入预期增长率和折现率（WACC），模型会根据其未来现金产生能力计算股票当前应有的价值。
WACC（加权平均资本成本）是 MRNA 估值中使用的折现率。较高的 WACC 会降低内在价值估算，较低的 WACC 则会提高。使用 MiniValuator 的敏感性热力图查看不同 WACC 假设对 MRNA DCF 估值结果的影响。
